- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01538732
Lichen Planus Mucosae at USZ, Efficacy of Oral Alitretinoin
Single-Center, Prospective, Open Label, Single-arm Pilot Study Investigating the Efficacy and Safety of Alitretinoin in Patients Suffering From Severe Mucosal Lichen Planus.
This is a single center, prospective, open label, single arm, investigator initiated pilot study investigating the effect of alitretinoin on severe lichen planus with mucosal manifestations. The target population comprises patients with MLP for at least 3 months, with or without LP lesions on other areas of the skin, who are refractory to topical therapy and standard skin care, and who are otherwise in good health. Patients will be recruited at the outpatient clinic of the dermatology department, University hospital Zurich.The planned duration of the study is 2 years. A total of 20 patients will be included. Patients who meet enrolment criteria will receive 30mg alitretinoin, given orally as gelatin capsules, once daily for 24 weeks. Dose interruptions are permitted in response to adverse effects, consistent with use of retinoids and the product label.
Most clinical evaluations will be performed every 4 weeks. A safety follow-up visit is planned 4 weeks after the end of treatment. Further follow-up visits will be conducted 16 and 24 weeks after end of treatment in those patients meeting the primary endpoint
- Trial with medicinal product
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Johanna Mangana, MD
- Email: johanna.mangana@usz.ch
Study Contact Backup
- Name: Reinhard Dummer, Professor, MD
- Email: reinhard.dummer@usz.ch
Study Locations
-
-
ZH
-
Zurich, ZH, Switzerland, 8091
- Recruiting
- University Hospital Zurich, Division of Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Aged 18 to 75 years
- MLP for at least 3 months
- Disease activity according to Escudier score of 10 points or greater or erosive lesion of any score
- Refractory to standard topical therapy
- Consensus to a 2 weeks wash-out period of topical steroids before starting study treatment
Exclusion criteria
- Unable to comply with the requirements of the study
- Pregnant or lactating women
- Female patients of childbearing potential who cannot use or will not commit to using two effective forms of contraception simultaneously under supervision of the investigator or a gynecologist
- Active hepatitis and/or vaccination against hepatitis A/B during the last 4 weeks
- Adequate control of the disease by standard topical therapy and standard topical corticosteroid therapy
- Known hypersensitivity to other retinoids or vitamin A derivatives, or to any study medication component
Patients treated with any of the following treatments 4 weeks before the start of study treatment:
- systemic drugs: corticosteroids, immunosuppressants, methotrexate
- phototherapy
- Treatment with any systemic or topical retinoids within 1 year or 1 month, respectively, before start of study treatment or treatment with systemic retinoids for treatment for MLP at any time
coexistence of any serious medical condition which, in the opinion of the investigator, may interfere with the safety of the patient, including
- hepatic insufficiency (alanine aminotransferase and /or aspartate aminotransferase values > 2.5 x ULN)
- severe renal failure
- uncontrolled hypertriglyceridemia (triglycerides >150 % of the upper limit of normal),
- uncontrolled hypercholesterolemia (cholesterol or low density lipoprotein (LDL) cholesterol values > 1.5 x ULN
- Patients with cardiovascular risk factors that would exclude a starting dose of 30 mg of alitretinoin
- Uncontrolled hypothyroidism
- Hypervitaminosis A
- Active major psychiatric disorder including depression and suicidal ideation
- Concomitant medications such as systemic tetracyclines, CYP3A4 inhibitors such as ketoconazole, Vitamin A or St. John's Wort within 1 week, or receiving systemic itraconazole within 2 weeks, before start of study treatment
- Trial participation within 2 months before start of study treatment (3 months for biologics)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of alitretinoin (Toctino®) based on the Escudier score of oral lesions at baseline and after 24 weeks of treatment.
Time Frame: 6 months
|
The primary objective is to determine the efficacy of alitretinoin (Toctino®) in reducing signs and symptoms of severe mucosal lichen planus with respect to the proportion of responders based on the, Escudier score of oral lesions at baseline and after 24 weeks of treatment or at the latest assessment for patients who withdrew prematurely (Last Observation Carried Forward, LOCF).
Response is defined as a 50 % reduction in the total Escudier score compared to the baseline values.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess the efficacy of alitretinoin over time in reduction of signs (e.g. ulcerations) or symptoms (e.g. pruritus), using VAS for pruritus and pain and OHIP
Time Frame: 6 months
|
6 months
|
Assess the time to response (time to 50 % reduction in the total Escudier score)
Time Frame: 6 months
|
6 months
|
Assess oral mucosal changes regarding inflammation and erosions, at treatment end compared to baseline using Escudier
Time Frame: 6 months
|
6 months
|
Assess the number/distribution of extramucosal skin lesions (papules) of LP at treatment end compared to baseline
Time Frame: 6 months
|
6 months
|
Assess, if applicable, the inflammatory infiltrate in mucosa and skin before and during alitretinoin therapy determined by histopathology taken before and 4 weeks after initiation of study treatment.
Time Frame: 4 weeks
|
4 weeks
|
Determine the relapse rate (relapse is defined as Escudier score or number of extramucosal papules increasing back to > 75% of baseline) within 24 week follow-up
Time Frame: 6 months
|
6 months
|
Assess safety of alitretinoin in mucosal lichen planus for the body as a whole
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Reinhard Dummer, Prof. MD, University Hospital Zurich, Division of Dermatology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LISZT-2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lichen Planus (LP)
-
Novartis PharmaceuticalsCompletedLichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen PlanopilarisGermany, United States, France
-
Cairo UniversityUnknownPatients With Oral Lichen PlanusEgypt
-
University of North Carolina, Chapel HillEli Lilly and CompanyRecruitingLichen Planus, Oral | Oral Lichen Planus | Lichen Planus, MucosalUnited States
-
Nourhan M.AlyAlexandria UniversityCompleted
-
Alexandria UniversityCompletedEvaluation of Diode Laser and Topical Steroid Therapy in the Treatment of Erosive Oral Lichen PlanusErosive Oral Lichen PlanusEgypt
-
Mashhad University of Medical SciencesUnknownTherapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen PlanusErosive Oral Lichen Planus | Atrophic Oral Lichen PlanusIran, Islamic Republic of
-
Pia Lopez JornetCompletedOral Lichen Planus | Oral Lichen Planus Related StressSpain
-
Panineeya Mahavidyalaya Institute of Dental Sciences...CompletedOral Lichen Planus Related StressIndia
-
Cairo UniversityCompletedErosive Oral Lichen PlanusEgypt
Clinical Trials on alitretinoin
-
Basilea PharmaceuticaCompletedHand DermatosesPoland, Germany, Canada
-
Stiefel, a GSK CompanyBasilea PharmaceuticaCompleted
-
University Hospital MuensterBasilea Pharmaceutica International LtdTerminatedLupus Erythematosus, CutaneousGermany
-
Basilea PharmaceuticaCompletedHand DermatosesGermany
-
Basilea PharmaceuticaCompleted
-
Basilea PharmaceuticaCompletedHand DermatosesGermany
-
Stiefel, a GSK CompanyBasilea PharmaceuticaCompletedPsoriasisFrance, Germany, United Kingdom, Netherlands
-
University Hospital, Gentofte, CopenhagenCompletedHepatic InsufficiencyDenmark
-
Anderson Clinical ResearchLigand PharmaceuticalsCompletedHIV Infections | Sarcoma, Kaposi
-
Anderson Clinical ResearchLigand PharmaceuticalsCompletedHIV Infections | Sarcoma, Kaposi